Brief: Stevanato Q2 Net Income EUR 29.7 Million Vs. IBES Estimate EUR 29.2 Million

Stevanato SpA

05/08/2025 11:30

Overview

Stevanato Q2 2025 revenue grows 8% yr/yr, beating analysts' expectations

Net income for Q2 beats analyst estimates

Company maintains fiscal 2025 guidance, indicating confidence in strategic plans

Outlook

Stevanato maintains fiscal 2025 revenue guidance of €1.160 bln to €1.190 bln

Company expects 2025 adjusted EBITDA between €288.5 mln and €301.8 mln

Stevanato forecasts 2025 adjusted diluted EPS of €0.50 to €0.54

Company says demand driven by pharmaceutical innovation and biologics

Result Drivers

BDS SEGMENT GROWTH - 10% increase in Biopharmaceutical and Diagnostic Solutions segment revenue driven by high-value syringes and increased production capacity at Latina and Fishers facilities

HIGH-VALUE SOLUTIONS - High-value solutions, including syringes, EZ-fill cartridges, and vials, represented 42% of total revenue, contributing significantly to qtr growth

ENGINEERING SEGMENT DECLINE - 2% revenue decline in Engineering Segment due to lower revenue from glass converting and unfavorable project mix

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
EUR 280 mln
EUR 268.30 mln (9 Analysts)
Q2 Net Income
Beat
EUR 29.70 mln
EUR 29.20 mln (9 Analysts)
Q2 Operating Income
Beat
EUR 41.40 mln
EUR 40 mln (9 Analysts)
Q2 Pretax Profit
Beat
EUR 39.10 mln
EUR 37.30 mln (7 Analysts)
Q2 Basic EPS
EUR 0.11
Q2 Gross Profit
EUR 78.60 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Stevanato Group SpA is $28.00, about 8.6% above its August 4 closing price of $25.58

The stock recently traded at 37 times the next 12-month earnings vs. a P/E of 32 three months ago

Press Release: ID:nBw1F5s9ga

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)